4-乙基-5-甲基-嘧啶 | 57562-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-乙基-5-甲基-嘧啶
• 英文名称: 4-ethyl-5-methyl-pyrimidine
• 英文别名: 4-Ethyl-5-methylpyrimidine；5-Methyl-4-ethylpyrimidin
• CAS: 57562-55-7
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: AFUNAWVZKQOGOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙基-5-甲基-嘧啶 、 甲酰胺 、 三氯氧磷 生成 N-{N-[1-hydroxy-2-(5-methyl-pyrimidin-4-yl)-propyl]-formimidoyl}-formamide
  参考文献：
  名称：

  KOYAMA T.; HIROTA T.; BASHO C.; WATANABE Y.; KITAUCHI Y.; SATOH Y.; OHMOR+, CHEM. AND PHARM. BULL. , 1976, 24, NO 7, 1459-1461

  摘要：

  DOI：
• 作为产物：
  描述：

  3-戊酮 以30%的产率得到
  参考文献：
  名称：

  KOYAMA T.; HIROTA T.; BASHOU C.; SATOH Y.; WATANABE Y.; MATSUMOTO S.; SHI+, CHEM. AND PHARM. BULL. , 1975, 23, NO 9, 2158-2161

  摘要：

  DOI：

文献信息

• PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BENAZET ALEXANDRE

  公开号：US20130079337A1

  公开（公告）日：2013-03-28

  The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1 , and also to the process for preparing them and to their therapeutic use.

  这项发明涉及与式（I）相对应的化合物，其中R1、R2和R3如权利要求1中所定义的，并且还涉及制备它们的过程以及它们的治疗用途。
• Direct access to pyrimidines through organocatalytic inverse-electron-demand Diels–Alder reaction of ketones with 1,3,5-triazine
  作者：Gongming Yang、Qianfa Jia、Lei Chen、Zhiyun Du、Jian Wang

  DOI：10.1039/c5ra16995j

  日期：——

  An organocatalytic inverse-electron-demand Diels–Alder reaction of ketones with 1,3,5-triazine through enamine catalysis has been developed.

  已开发了一种通过烯胺催化的酮与1,3,5-三嗪之间的有机催化反向电子需求Diels-Alder反应。
• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Qiao Jennifer

  公开号：US20100197716A1

  公开（公告）日：2010-08-05

  The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y 1 receptor which can be used as medicaments.

  本发明提供了一种新型尿素，包含式（I）中的N-芳基或N-杂环芳基取代的杂环，或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、B、D和W如本文所定义。这些化合物是人类P2Y1受体的选择性抑制剂，可用作药物。
• AZEPINO[4,5-B]INDOLES AND METHODS OF USE
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190295A1

  公开（公告）日：2013-07-25

  This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

  本披露涉及新的azepino [4,5-b] indole化合物，可用于调节个体中的组胺受体。描述了新的化合物，包括新的1,2,3,4,5,6-四氢azepino [4,5-b] indoles。还提供了药物组合物。